Portfolio company Sparrow Pharmaceuticals closed a $95M Series B for its Type 2 diabetes therapy.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics to improve outcomes for patients struggling with type 2 diabetes and related metabolic conditions
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics to improve outcomes for patients struggling with type 2 diabetes and related metabolic conditions.